{"id":"chs-0214","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Immune-related adverse events"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a bispecific T-cell engager (BiTE), CHS-0214 bridges cytotoxic T lymphocytes to tumor cells by binding CD3 on T cells with one arm and a tumor antigen with the other arm, thereby activating and redirecting T cells to recognize and eliminate cancer cells. This mechanism bypasses the need for traditional T-cell receptor recognition and can enhance anti-tumor immunity in solid tumors.","oneSentence":"CHS-0214 is a bispecific antibody that simultaneously engages CD3 on T cells and a tumor-associated antigen to redirect immune cells to kill cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:05:49.094Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (specific indication under clinical development)"}]},"trialDetails":[{"nctId":"NCT02134210","phase":"PHASE3","title":"Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2014-06-16","conditions":"Plaque Psoriasis","enrollment":521},{"nctId":"NCT02115750","phase":"PHASE3","title":"Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2014-05","conditions":"Rheumatoid Arthritis","enrollment":647},{"nctId":"NCT02486939","phase":"PHASE3","title":"A Long Term Safety Extension Study (CHS-0214-05)","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2015-07","conditions":"Rheumatoid Arthritis, Plaque Psoriasis","enrollment":359}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CHS-0214","genericName":"CHS-0214","companyName":"Coherus Oncology, Inc.","companyId":"coherus-oncology-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CHS-0214 is a bispecific antibody that simultaneously engages CD3 on T cells and a tumor-associated antigen to redirect immune cells to kill cancer cells. Used for Solid tumors (specific indication under clinical development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}